Genitope plans follow-on of 4.5 million shares via WR Hambrecht

By Ronda Fears

Nashville, Jan. 23 - Genitope Corp. on Monday announced plans for a follow-on offering of 4.5 million shares of common stock via bookrunner WR Hambrecht & Co.

RBC Capital is joint lead manager. Co-managers are Brean Murray, Carret & Co. LLC and Punk, Ziegel & Co.

There is a greenshoe of 675,000 shares available.

Redwood City, Calif.-based Genitope is focused on cancer treatments. Its lead product candidate, MyVax Personalized Immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells.

Genitope shares fell Monday by 89 cents, or 9.68%, to $8.30 (Nasdaq: GTOP).

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.